RxDoctor Payments Data

Cameron Barnes, MD

Urology · Richmond, VANPI 1437113982

Payments from drug & device makers

$4,117in general payments, 2019–2025

Across 164 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$808
  • Blue Earth Diagnostics$606
  • AbbVie$455
  • Boston Scientific$429
  • Pfizer$327
  • Medtronic$231
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$4,097100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,117 in reported general payments places this provider in the 55th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$480,014
Medicare patients
1,308
Services billed
42,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide27$390,981
NubeqaDarolutamide26$326,320
OrgovyxRelugolix33$86,459
MyrbetriqMirabegron45$34,134
GemtesaVibegron33$24,701
Silodosin209$21,268
Dutasteride486$16,531
Tamsulosin Hcl827$11,113
ElmironPentosan Polysulfate Sodium13$8,911
Mirabegron ErMirabegron11$5,719
Solifenacin Succinate98$5,396
Trospium Chloride87$4,861
Finasteride330$4,700
Tolterodine Tartrate ErTolterodine Tartrate39$4,616
Tadalafil20$4,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$73$425,11572 claims
BayerNubeqa$59$326,32026 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$93$111,16066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →